D. E. Shaw & Co., Inc. Ascendis Pharma A/S Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 90,380 shares of ASND stock, worth $11.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
90,380Holding current value
$11.2 Million% of portfolio
0.01%Shares
27 transactions
Others Institutions Holding ASND
# of Institutions
243Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.21 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$639 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$621 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$549 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$521 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $6.94B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...